EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q3 EPS of ($0.85), $0.08 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $966 thousand versus the consensus estimate of $3.46 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.